SCHEDULE 13G/A: Invesco Ltd. Discloses 4.8% Passive Stake in ADMA Biologics Inc.

Invesco Ltd. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.8% in ADMA Biologics Inc. as of December 31, 2024.

Summary

• Invesco Ltd., a Bermuda-based parent holding company and investment adviser, has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in ADMA Biologics Inc.
• As of December 31, 2024, Invesco Ltd. beneficially owns an aggregate of 11,296,255 shares of ADMA Biologics Inc. Common Stock.
• This ownership represents 4.8% of the class of securities.
• Invesco Ltd. holds sole voting power over 10,692,790 shares and sole dispositive power over 11,296,255 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or Invesco Ltd.'s future investment intentions beyond the passive nature of the stake.

Industry Context

This filing is a standard regulatory disclosure for institutional investors like Invesco Ltd. when their beneficial ownership in a public company reaches or changes significantly around the 5% threshold, indicating a passive investment position rather than an intent to influence control.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company.

Key Dates

Keywords

ADMA Biologics Inc, Invesco Ltd., Schedule 13G, SEC filing, beneficial ownership, institutional investment, common stock, passive stake